22 studies found for:    Empagliflozin | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo
2 Completed Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin low dose qd;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
3 Recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
4 Completed Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo
5 Recruiting Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
6 Completed
Has Results
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Empagliflozin
7 Withdrawn Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo;   Drug: Sitagliptin
8 Recruiting Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Empagliflozin;   Drug: Placebo
9 Completed
Has Results
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Placebo;   Drug: Sitagliptin 100mg
10 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI10773 high dose;   Drug: BI 10773;   Drug: BI 10773 open label;   Drug: Placebo identical to BI10773 low dose;   Drug: Placebo identical to Sitagliptin 100mg;   Drug: BI10773;   Drug: Sitagliptin
11 Completed
Has Results
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI 10773 high dose;   Drug: Placebo identical to BI 10773 low dose;   Drug: BI 10773
12 Completed BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose
13 Completed
Has Results
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Placebo;   Drug: BI 10773
14 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Conditions: Diabetes Mellitus, Type 2;   Renal Insufficiency
Interventions: Drug: BI 10773;   Drug: Placebo
15 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: BI 10773
16 Completed
Has Results
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin;   Drug: BI 10773;   Drug: Placebo (low dose);   Drug: Placebo (high dose)
17 Completed Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo
18 Completed
Has Results
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Obesity
Interventions: Drug: Placebo;   Drug: BI 10773
19 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: high dose FDC;   Drug: BI 10773 high dose;   Drug: high dose FDC placebo;   Drug: low dose FDC placebo;   Drug: high dose BI 10773 placebo;   Drug: low dose FDC;   Drug: BI 10773 low dose;   Drug: linagliptin;   Drug: linagliptin placebo;   Drug: BI 10773 low dose placebo;   Drug: low dose BI 10773 placebo
20 Active, not recruiting
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Glimepiride;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years